Bruker Corporation (NASDAQ:BRKR) Given Average Recommendation of “Hold” by Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have been given a consensus recommendation of “Hold” by the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $52.2857.

BRKR has been the subject of a number of recent research reports. Wells Fargo & Company increased their target price on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. UBS Group increased their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Zacks Research raised Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. Rothschild Redb raised shares of Bruker to a “strong-buy” rating in a report on Thursday, November 20th. Finally, Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research note on Wednesday, December 10th.

Bruker Stock Down 4.7%

BRKR opened at $50.88 on Wednesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. The business has a 50 day moving average price of $46.64 and a 200 day moving average price of $39.87. The firm has a market cap of $7.73 billion, a P/E ratio of -318.00, a price-to-earnings-growth ratio of 6.89 and a beta of 1.17. Bruker has a twelve month low of $28.53 and a twelve month high of $63.95.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Research analysts forecast that Bruker will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Bruker’s dividend payout ratio is currently -125.00%.

Insider Transactions at Bruker

In related news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This trade represents a 5.17% decrease in their position. The SEC filing for this sale provides additional information. 27.30% of the stock is currently owned by company insiders.

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently modified their holdings of BRKR. Nisa Investment Advisors LLC lifted its stake in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after buying an additional 487 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Huntington National Bank grew its position in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the last quarter. Spire Wealth Management bought a new position in shares of Bruker during the second quarter worth approximately $32,000. Finally, Parallel Advisors LLC lifted its holdings in Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after purchasing an additional 347 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.